Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Overview of Hodgkin lymphoma in children and adolescents

Kenneth L McClain, MD, PhD
Kala Kamdar, MD, MS Epi
Section Editor
Julie R Park, MD
Deputy Editor
Alan G Rosmarin, MD


Hodgkin lymphoma (HL, formerly called Hodgkin's disease) is a malignant lymphoma that accounts for approximately 7 percent of childhood cancers and 1 percent of childhood cancer deaths in the United States (table 1) [1]. The incidence of HL in childhood varies by age such that HL is exceedingly rare in infants, but is the most common childhood cancer in the 15- to 19-year-old age group. Children and adolescents with HL have a five-year survival of 94 percent since 2002 compared with an 81 percent survival in the early 1970s [2].

Few risk factors, other than those related to viral exposure and immune function, have been convincingly identified. (See "The role of Epstein-Barr virus in Hodgkin lymphoma" and "The Reed-Sternberg cell and the pathogenesis of Hodgkin lymphoma".)

This topic will provide an overview of HL in children and adolescents. The pathobiology of HL and its diagnosis and management in adults are presented separately as is the care of the adult survivor of HL. (See "Overview of the approach to the adult survivor of classical Hodgkin lymphoma" and "Initial evaluation and diagnosis of classical Hodgkin lymphoma in adults" and "Overview of the treatment of classical Hodgkin lymphoma in adults".)


Variation in the incidence, age, and sex distribution of HL occurs in different populations according to geographic location, socioeconomic status, and immunologic status. In the United States and other economically advantaged countries, two incidence peaks exist: one in young adults and one in persons older than 50 years; most patients are young adults (figure 1) [1,3]. The estimated age-related incidence rates are 29 cases per million per year in adolescents aged 15 to 19; approximately 10 per million per year in 10- to 14-year-olds; 3.5 per million in five- to nine-year-olds; and one per million for ages zero to four years. The bimodal age distribution of HL is different in economically disadvantaged areas. An initial peak occurs in childhood for boys, relatively low rates are found in young adults, and a late peak occurs in older adults [4]. (See "Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma", section on 'Incidence and age distribution'.)

The overall incidence of HL in adolescents is greater in females than in males (male to female ratio 0.8); however, boys under age 15 have higher incidence of HL, with up to fivefold higher incidence of HL in boys than girls less than five years of age [5]. The incidence of HL is similar among White and African-American children younger than 10 years of age, but is increased among White children relative to African Americans older than 10 years (ratio of 1.4:1) [5].

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Aug 21, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Ward E, DeSantis C, Robbins A, et al. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 2014; 64:83.
  2. Smith MA, Seibel NL, Altekruse SF, et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 2010; 28:2625.
  3. Ries LA, Kosary CL, Hankey BF, et al. (Eds). SEER cancer statistics review: 1973-1994. NIH publ no. 97-2789. Bethesda: National Cancer Institute, 1997.
  4. Correa P, O'Conor GT. Epidemiologic patterns of Hodgkin's disease. Int J Cancer 1971; 8:192.
  5. Percy CL, Smith MA, Linet M. Lymphomas and reticuloendothelial neoplasms. In: Cancer Incidence and Survival among Children and Adolescents: United States SEER Program, 1975-1995, Ries LA, Smith MA, Gurney JG, et al. (Eds), National Cancer Institute, Bethesda, MD 1999. p.35.
  6. Ferraris AM, Racchi O, Rapezzi D, et al. Familial Hodgkin's disease: a disease of young adulthood? Ann Hematol 1997; 74:131.
  7. Crump C, Sundquist K, Sieh W, et al. Perinatal and family risk factors for Hodgkin lymphoma in childhood through young adulthood. Am J Epidemiol 2012; 176:1147.
  8. Linabery AM, Erhardt EB, Richardson MR, et al. Family history of cancer and risk of pediatric and adolescent Hodgkin lymphoma: A Children's Oncology Group study. Int J Cancer 2015; 137:2163.
  9. Bräuninger A, Schmitz R, Bechtel D, et al. Molecular biology of Hodgkin's and Reed/Sternberg cells in Hodgkin's lymphoma. Int J Cancer 2006; 118:1853.
  10. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC Press, Lyon 2008.
  11. Bazzeh F, Rihani R, Howard S, Sultan I. Comparing adult and pediatric Hodgkin lymphoma in the Surveillance, Epidemiology and End Results Program, 1988-2005: an analysis of 21 734 cases. Leuk Lymphoma 2010; 51:2198.
  12. Slack GW, Ferry JA, Hasserjian RP, et al. Lymphocyte depleted Hodgkin lymphoma: an evaluation with immunophenotyping and genetic analysis. Leuk Lymphoma 2009; 50:937.
  13. Nachman JB, Sposto R, Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 2002; 20:3765.
  14. Kebudi R, Ayan I, Erseven G, et al. Hypertrophic osteoarthropathy and intrathoracic Hodgkin disease of childhood. Med Pediatr Oncol 1997; 29:578.
  15. Atkinson MK, McElwain TJ, Peckham MJ, Thomas PP. Hypertrophic pulmonary osteoarthropathy in Hodgkin's disease: reversal with chemotherapy. Cancer 1976; 38:1729.
  16. Ansari N, Qureshi A, Hall GW. Images in haematology. Hypertrophic pulmonary osteoarthropathy in mediastinal Hodgkin lymphoma in childhood. Br J Haematol 2010; 150:130.
  17. Gobbi PG, Cavalli C, Gendarini A, et al. Reevaluation of prognostic significance of symptoms in Hodgkin's disease. Cancer 1985; 56:2874.
  18. Seymour JF. Splenomegaly, eosinophilia, and pruritus: Hodgkin's disease, or...? Blood 1997; 90:1719.
  19. Olsson H, Brandt L. Relief of pruritus as an early sign of spinal cord compression in Hodgkin's disease. Acta Med Scand 1979; 206:319.
  20. Stefanato CM, Reyes-Mugica M. Masked Hodgkin's disease: the pruriginous disguise. Pediatr Hematol Oncol 1996; 13:293.
  21. Cavalli F. Rare syndromes in Hodgkin's disease. Ann Oncol 1998; 9 Suppl 5:S109.
  22. Callahan BC, Coe R, Place HM. Hodgkin disease of the spine presenting as alcohol-related pain. A case report and review of the literature. J Bone Joint Surg Am 1994; 76:119.
  23. Bergmann J, Buchheidt D, Waldherr R, et al. IgA nephropathy and hodgkin's disease: a rare coincidence. Case report and literature review. Am J Kidney Dis 2005; 45:e16.
  24. Sills RH. The spleen and lymph nodes. In: Oski's Pediatrics. Principles and Practice, 4th ed, McMillan JA, Feigin RD, DeAngelis C, Jones MD (Eds), Lippincott, Williams & Wilkins, Philadelphia 2006. p.1717.
  25. Heiberg E, Wolverson MK, Sundaram M, Nouri S. Normal thymus: CT characteristics in subjects under age 20. AJR Am J Roentgenol 1982; 138:491.
  26. Rostock RA, Siegelman SS, Lenhard RE, et al. Thoracic CT scanning for mediastinal Hodgkin's disease: results and therapeutic implications. Int J Radiat Oncol Biol Phys 1983; 9:1451.
  27. Baker LL, Parker BR, Donaldson SS, Castellino RA. Staging of Hodgkin disease in children: comparison of CT and lymphography with laparotomy. AJR Am J Roentgenol 1990; 154:1251.
  28. Robertson VL, Anderson CS, Keller FG, et al. Role of FDG-PET in the definition of involved-field radiation therapy and management for pediatric Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 2011; 80:324.
  29. Sioka C. The utility of FDG PET in diagnosis and follow-up of lymphoma in childhood. Eur J Pediatr 2013; 172:733.
  30. Mahoney DH Jr, Schreuders LC, Gresik MV, McClain KL. Role of staging bone marrow examination in children with Hodgkin disease. Med Pediatr Oncol 1998; 30:175.
  31. Murphy SB. The national impact of clinical cooperative group trials for pediatric cancer. Med Pediatr Oncol 1995; 24:279.
  32. Corrigan JJ, Feig SA, American Academy of Pediatrics. Guidelines for pediatric cancer centers. Pediatrics 2004; 113:1833.
  33. Foltz LM, Song KW, Connors JM. Hodgkin's lymphoma in adolescents. J Clin Oncol 2006; 24:2520.
  34. Hudson MM, Donaldson SS. Hodgkin's disease. In: Principles and Practice of Pediatric Oncology, 5th ed, Pizzo PA, Poplack DG (Eds), Lippincott Williams & Wilkins, Philadelphia 2006. p.695.
  35. Yung L, Smith P, Hancock BW, et al. Long term outcome in adolescents with Hodgkin's lymphoma: poor results using regimens designed for adults. Leuk Lymphoma 2004; 45:1579.
  36. Dörffel W, Rühl U, Lüders H, et al. Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95. J Clin Oncol 2013; 31:1562.
  37. Donaldson SS, Link MP, Weinstein HJ, et al. Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease. J Clin Oncol 2007; 25:332.
  38. Schwartz CL, Constine LS, Villaluna D, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood 2009; 114:2051.
  39. Tebbi CK, Mendenhall NP, London WB, et al. Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group. Pediatr Blood Cancer 2012; 59:1259.
  40. Rühl U, Albrecht M, Dieckmann K, et al. Response-adapted radiotherapy in the treatment of pediatric Hodgkin's disease: an interim report at 5 years of the German GPOH-HD 95 trial. Int J Radiat Oncol Biol Phys 2001; 51:1209.
  41. Keller FG, Nachman J, Constine L, et al. A phase III study for the treatment of children and adolescents with newly diagnosed low risk Hodgkin lymphoma (HL). Blood 2010; 116:A767.
  42. Mauz-Körholz C, Hasenclever D, Dörffel W, et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol 2010; 28:3680.
  43. Friedman DL, Chen L, Wolden S, et al. Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031. J Clin Oncol 2014; 32:3651.
  44. Charpentier AM, Friedman DL, Wolden S, et al. Predictive Factor Analysis of Response-Adapted Radiation Therapy for Chemotherapy-Sensitive Pediatric Hodgkin Lymphoma: Analysis of the Children's Oncology Group AHOD 0031 Trial. Int J Radiat Oncol Biol Phys 2016; 96:943.
  45. Kelly KM, Sposto R, Hutchinson R, et al. BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group. Blood 2011; 117:2596.
  46. Friedmann AM, Hudson MM, Weinstein HJ, et al. Treatment of unfavorable childhood Hodgkin's disease with VEPA and low-dose, involved-field radiation. J Clin Oncol 2002; 20:3088.
  47. Hudson MM, Krasin M, Link MP, et al. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease. J Clin Oncol 2004; 22:4541.
  48. Shankar A, Visaduraki M, Hayward J, et al. Clinical outcome in children and adolescents with Hodgkin lymphoma after treatment with chemotherapy alone - the results of the United Kingdom HD3 national cohort trial. Eur J Cancer 2012; 48:108.
  49. Shankar A, Daw S. Nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents--a comprehensive review of biology, clinical course and treatment options. Br J Haematol 2012; 159:288.
  50. Kraus MD, Haley J. Lymphocyte predominance Hodgkin's disease: the use of bcl-6 and CD57 in diagnosis and differential diagnosis. Am J Surg Pathol 2000; 24:1068.
  51. Mauz-Körholz C, Gorde-Grosjean S, Hasenclever D, et al. Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma. Cancer 2007; 110:179.
  52. Appel BE, Chen L, Buxton AB, et al. Minimal Treatment of Low-Risk, Pediatric Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the Children's Oncology Group. J Clin Oncol 2016; 34:2372.
  53. Shankar A, Hall GW, Gorde-Grosjean S, et al. Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin's lymphoma - an Anglo-French collaborative report. Eur J Cancer 2012; 48:1700.
  54. Pellegrino B, Terrier-Lacombe MJ, Oberlin O, et al. Lymphocyte-predominant Hodgkin's lymphoma in children: therapeutic abstention after initial lymph node resection--a Study of the French Society of Pediatric Oncology. J Clin Oncol 2003; 21:2948.
  55. Murphy SB, Morgan ER, Katzenstein HM, Kletzel M. Results of little or no treatment for lymphocyte-predominant Hodgkin disease in children and adolescents. J Pediatr Hematol Oncol 2003; 25:684.
  56. Metzger ML, Weinstein HJ, Hudson MM, et al. Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma. JAMA 2012; 307:2609.
  57. Appel BE, Chen L, Buxton A, et al. Impact of low-dose involved-field radiation therapy on pediatric patients with lymphocyte-predominant Hodgkin lymphoma treated with chemotherapy: a report from the Children's Oncology Group. Pediatr Blood Cancer 2012; 59:1284.
  58. Rathore N, Eissa HM, Margolin JF, et al. Pediatric Hodgkin lymphoma: are we over-scanning our patients? Pediatr Hematol Oncol 2012; 29:415.
  59. Harker-Murray PD, Drachtman RA, Hodgson DC, et al. Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma. Pediatr Blood Cancer 2014; 61:579.
  60. Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001; 97:616.
  61. Gorde-Grosjean S, Oberlin O, Leblanc T, et al. Outcome of children and adolescents with recurrent/refractory classical Hodgkin lymphoma, a study from the Société Française de Lutte contre le Cancer des Enfants et des Adolescents (SFCE). Br J Haematol 2012; 158:649.
  62. Schellong G, Dörffel W, Claviez A, et al. Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group. J Clin Oncol 2005; 23:6181.
  63. Wirth A, Corry J, Laidlaw C, et al. Salvage radiotherapy for Hodgkin's disease following chemotherapy failure. Int J Radiat Oncol Biol Phys 1997; 39:599.
  64. Cairo MS, Shen V, Krailo MD, et al. Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report. J Pediatr Hematol Oncol 2001; 23:30.
  65. Bonfante V, Viviani S, Santoro A, et al. Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease. Br J Haematol 1998; 103:533.
  66. Cole PD, Schwartz CL, Drachtman RA, et al. Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a children's oncology group report. J Clin Oncol 2009; 27:1456.
  67. Sandlund JT, Pui CH, Mahmoud H, et al. Efficacy of high-dose methotrexate, ifosfamide, etoposide and dexamethasone salvage therapy for recurrent or refractory childhood malignant lymphoma. Ann Oncol 2011; 22:468.
  68. Schulz H, Rehwald U, Morschhauser F, et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 2008; 111:109.
  69. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012; 30:2183.
  70. Kelly KM, Hodgson D, Appel B, et al. Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma. Pediatr Blood Cancer 2013; 60:972.
  71. LaCasce AS, Bociek G, Sawas A, et al. Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma. Blood (ASH Annual Meeting Abstracts) 2015; 126:3982.
  72. Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 2016; 17:1283.
  73. Lieskovsky YE, Donaldson SS, Torres MA, et al. High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: results and prognostic indices. J Clin Oncol 2004; 22:4532.
  74. Harris RE, Termuhlen AM, Smith LM, et al. Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children's Oncology Group study A5962. Biol Blood Marrow Transplant 2011; 17:249.
  75. Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003; 31:667.
  76. Morabito F, Stelitano C, Luminari S, et al. The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL). Bone Marrow Transplant 2006; 37:283.
  77. Moskowitz CH, Kewalramani T, Nimer SD, et al. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 2004; 124:645.
  78. Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015; 385:1853.
  79. Thomson AB, Wallace WH. Treatment of paediatric Hodgkin's disease. a balance of risks. Eur J Cancer 2002; 38:468.
  80. Johnston WT, Lightfoot TJ, Simpson J, Roman E. Childhood cancer survival: a report from the United Kingdom Childhood Cancer Study. Cancer Epidemiol 2010; 34:659.
  81. Pinkerton R, Wills RA, Coory MD, Fraser CJ. Survival from haematological malignancy in childhood, adolescence and young adulthood in Australia: is the age-related gap narrowing? Med J Aust 2010; 193:217.
  82. Smith RS, Chen Q, Hudson MM, et al. Prognostic factors for children with Hodgkin's disease treated with combined-modality therapy. J Clin Oncol 2003; 21:2026.
  83. Krasin MJ, Rai SN, Kun LE, et al. Patterns of treatment failure in pediatric and young adult patients with Hodgkin's disease: local disease control with combined-modality therapy. J Clin Oncol 2005; 23:8406.
  84. Metzger ML, Castellino SM, Hudson MM, et al. Effect of race on the outcome of pediatric patients with Hodgkin's lymphoma. J Clin Oncol 2008; 26:1282.
  85. Friedman DI, Wolden S, Constine L, et al. AHOD0031: A Phase III Study of Dose-Intensive Therapy for Intermediate Risk Hodgkin Lymphoma: A Report From the Children's Oncology Group. Blood 2010; 116:Abstract 766.
  86. Neglia JP, Friedman DL, Yasui Y, et al. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst 2001; 93:618.
  87. Ng AK, Bernardo MP, Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 2002; 20:2101.
  88. Mefferd JM, Donaldson SS, Link MP. Pediatric Hodgkin's disease: pulmonary, cardiac, and thyroid function following combined modality therapy. Int J Radiat Oncol Biol Phys 1989; 16:679.
  89. Hudson MM, Mertens AC, Yasui Y, et al. Health status of adult long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. JAMA 2003; 290:1583.
  90. Kadan-Lottick NS, Zeltzer LK, Liu Q, et al. Neurocognitive functioning in adult survivors of childhood non-central nervous system cancers. J Natl Cancer Inst 2010; 102:881.
  91. Castellino SM, Geiger AM, Mertens AC, et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood 2011; 117:1806.
  92. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006; 355:1572.
  93. Donaldson SS, Hancock SL, Hoppe RT. The Janeway lecture. Hodgkin's disease--finding the balance between cure and late effects. Cancer J Sci Am 1999; 5:325.
  94. Schellong G. Pediatric Hodgkin's disease: treatment in the late 1990s. Ann Oncol 1998; 9 Suppl 5:S115.
  95. Chow LM, Nathan PC, Hodgson DC, et al. Survival and late effects in children with Hodgkin's lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation. J Clin Oncol 2006; 24:5735.
  96. Armstrong GT, Chen Y, Yasui Y, et al. Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer. N Engl J Med 2016; 374:833.
  97. Willman KY, Cox RS, Donaldson SS. Radiation induced height impairment in pediatric Hodgkin's disease. Int J Radiat Oncol Biol Phys 1994; 28:85.
  98. Constine LS, Donaldson SS, McDougall IR, et al. Thyroid dysfunction after radiotherapy in children with Hodgkin's disease. Cancer 1984; 53:878.
  99. Samaan NA, Schultz PN, Yang KP, et al. Endocrine complications after radiotherapy for tumors of the head and neck. J Lab Clin Med 1987; 109:364.
  100. Shafford EA, Kingston JE, Healy JC, et al. Thyroid nodular disease after radiotherapy to the neck for childhood Hodgkin's disease. Br J Cancer 1999; 80:808.
  101. Thibaud E, Ramirez M, Brauner R, et al. Preservation of ovarian function by ovarian transposition performed before pelvic irradiation during childhood. J Pediatr 1992; 121:880.
  102. Williams RS, Littell RD, Mendenhall NP. Laparoscopic oophoropexy and ovarian function in the treatment of Hodgkin disease. Cancer 1999; 86:2138.
  103. Le Floch O, Donaldson SS, Kaplan HS. Pregnancy following oophoropexy and total nodal irradiation in women with Hodgkin's disease. Cancer 1976; 38:2263.
  104. Radford JA, Lieberman BA, Brison DR, et al. Orthotopic reimplantation of cryopreserved ovarian cortical strips after high-dose chemotherapy for Hodgkin's lymphoma. Lancet 2001; 357:1172.
  105. Demeestere I, Simon P, Emiliani S, et al. Fertility preservation: successful transplantation of cryopreserved ovarian tissue in a young patient previously treated for Hodgkin's disease. Oncologist 2007; 12:1437.
  106. Oktay K, Türkçüoğlu I, Rodriguez-Wallberg KA. Four spontaneous pregnancies and three live births following subcutaneous transplantation of frozen banked ovarian tissue: what is the explanation? Fertil Steril 2011; 95:804.e7.
  107. Ben Arush MW, Solt I, Lightman A, et al. Male gonadal function in survivors of childhood Hodgkin and non-Hodgkin lymphoma. Pediatr Hematol Oncol 2000; 17:239.
  108. Botchan A, Hauser R, Gamzu R, et al. Sperm quality in Hodgkin's disease versus non-Hodgkin's lymphoma. Hum Reprod 1997; 12:73.
  109. Brämswig JH, Riepenhausen M, Schellong G. Parenthood in adult female survivors treated for Hodgkin's lymphoma during childhood and adolescence: a prospective, longitudinal study. Lancet Oncol 2015; 16:667.
  110. Hancock SL, Donaldson SS, Hoppe RT. Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol 1993; 11:1208.
  111. Scholz KH, Herrmann C, Tebbe U, et al. Myocardial infarction in young patients with Hodgkin's disease--potential pathogenic role of radiotherapy, chemotherapy, and splenectomy. Clin Investig 1993; 71:57.
  112. Hicks GL Jr. Coronary artery operation in radiation-associated atherosclerosis: long-term follow-up. Ann Thorac Surg 1992; 53:670.
  113. Adams MJ, Lipsitz SR, Colan SD, et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 2004; 22:3139.
  114. Bowers DC, McNeil DE, Liu Y, et al. Stroke as a late treatment effect of Hodgkin's Disease: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2005; 23:6508.
  115. Bhakta N, Liu Q, Yeo F, et al. Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin's lymphoma: an analysis from the St Jude Lifetime Cohort Study. Lancet Oncol 2016; 17:1325.
  116. Galper SL, Yu JB, Mauch PM, et al. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood 2011; 117:412.
  117. Donaldson SS, Kaplan HS. Complications of treatment of Hodgkin's disease in children. Cancer Treat Rep 1982; 66:977.
  118. Bossi G, Cerveri I, Volpini E, et al. Long-term pulmonary sequelae after treatment of childhood Hodgkin's disease. Ann Oncol 1997; 8 Suppl 1:19.
  119. Marina NM, Greenwald CA, Fairclough DL, et al. Serial pulmonary function studies in children treated for newly diagnosed Hodgkin's disease with mantle radiotherapy plus cycles of cyclophosphamide, vincristine, and procarbazine alternating with cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine. Cancer 1995; 75:1706.
  120. O'Brien MM, Donaldson SS, Balise RR, et al. Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy. J Clin Oncol 2010; 28:1232.
  121. Bhatia S, Yasui Y, Robison LL, et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol 2003; 21:4386.
  122. Wolden SL, Lamborn KR, Cleary SF, et al. Second cancers following pediatric Hodgkin's disease. J Clin Oncol 1998; 16:536.
  123. Hudson MM, Poquette CA, Lee J, et al. Increased mortality after successful treatment for Hodgkin's disease. J Clin Oncol 1998; 16:3592.
  124. Lin HM, Teitell MA. Second malignancy after treatment of pediatric Hodgkin disease. J Pediatr Hematol Oncol 2005; 27:28.
  125. Guibout C, Adjadj E, Rubino C, et al. Malignant breast tumors after radiotherapy for a first cancer during childhood. J Clin Oncol 2005; 23:197.
  126. van Leeuwen FE, Klokman WJ, Veer MB, et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 2000; 18:487.
  127. Alm El-Din MA, Hughes KS, Finkelstein DM, et al. Breast cancer after treatment of Hodgkin's lymphoma: risk factors that really matter. Int J Radiat Oncol Biol Phys 2009; 73:69.
  128. Henderson TO, Amsterdam A, Bhatia S, et al. Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer. Ann Intern Med 2010; 152:444.
  129. Le Deley MC, Leblanc T, Shamsaldin A, et al. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Société Française d'Oncologie Pédiatrique. J Clin Oncol 2003; 21:1074.
  130. Sklar C, Whitton J, Mertens A, et al. Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2000; 85:3227.